France· FR:64726914
NECYRANE, solution pour pulvérisation nasale
A medicinal product containing ritiométan magnésien, registered in France by PIERRE FABRE MEDICAMENT.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- RITIOMÉTAN MAGNÉSIEN
- Manufacturer
- PIERRE FABRE MEDICAMENT
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009307051551 flacon(s) pressurisé(e)(s) en verre de 10 ml avec tube plongeur polyéthylène haute densité (PEHD)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d65201ba-6304-430e-bbd5-078774073757 GET /v1/drugs/d65201ba-6304-430e-bbd5-078774073757?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64726914",
"date_amm": "1996-08-06",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "RITIOMÉTAN MAGNÉSIEN",
"statut_amm": "Autorisation abrogée",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "solution pour pulvérisation",
"voies_administration": "nasale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about ritiométan magnésien.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.